Rentokil Initial plc Sponsored ADR (RTO)
NYSE NYSE Primary 
XFRA 
In all-hands meeting, Amazon CEO says RTO mandate not a 'backdoor layoff'
Business Insider obtained a recording of Amazon CEO Andy Jassy's latest all-hands meeting. Jassy said Amazon's RTO policy is not a 'backdoor layoff' strategy.
RTO ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Rentokil Initial plc
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rentokil Initial plc ("Rentokil Initial plc") (NYSE:RTO) concerning possible violations of federal securities laws. Rentokil disclosed on September 11, 2024, that it expected full-year adjusted pretax profit of approximately £700 million, compared to £766 million in the previous year, citing weaker than expected sales in North America, the Company's largest market.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rentokil Initial plc - RTO
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Rentokil Initial plc ("Rentokil" or the "Company") (NYSE:RTO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Levi & Korsinsky Reminds Shareholders of an Investigation into Rentokil Initial plc (RTO) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rentokil Initial plc ("Rentokil Initial plc") (NYSE:RTO) concerning possible violations of federal securities laws. Rentokil disclosed on September 11, 2024, that it expected full-year adjusted pretax profit of approximately £700 million, compared to £766 million in the previous year, citing weaker than expected sales in North America, the Company's largest market.
Shareholders Are Invited To Join The Schall Law Firm's Inquiry Into Rentokil Initial plc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rentokil Initial plc ("Rentokil" or "the Company") (NYSE:RTO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Rentokil Initial plc (RTO) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / November 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rentokil Initial plc ("Rentokil Initial plc") (NYSE:RTO) concerning possible violations of federal securities laws. Rentokil disclosed on September 11, 2024, that it expected full-year adjusted pretax profit of approximately £700 million, compared to £766 million in the previous year, citing weaker than expected sales in North America, the Company's largest market.
Rentokil Initial plc Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Investor Participation
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rentokil Initial plc ("Rentokil" or "the Company") (NYSE:RTO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Announces an Investigation on Behalf of Rentokil Initial plc (RTO) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / November 2, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rentokil Initial plc ("Rentokil Initial plc") (NYSE:RTO) concerning possible violations of federal securities laws. Rentokil disclosed on September 11, 2024, that it expected full-year adjusted pretax profit of approximately £700 million, compared to £766 million in the previous year, citing weaker than expected sales in North America, the Company's largest market.
Shareholders Are Invited To Join The Schall Law Firm In An Inquiry Into Rentokil Initial plc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rentokil Initial plc ("Rentokil" or "the Company") (NYSE:RTO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Announces an Investigation on Behalf of Rentokil Initial plc (RTO) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Rentokil Initial plc ("Rentokil Initial plc") (NYSE:RTO) concerning possible violations of federal securities laws. Rentokil disclosed on September 11, 2024, that it expected full-year adjusted pretax profit of approximately £700 million, compared to £766 million in the previous year, citing weaker than expected sales in North America, the Company's largest market.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rentokil Initial plc - RTO
NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Rentokil Initial plc ("Rentokil" or the "Company") (NYSE:RTO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Verisante Technology, Inc. Announces Update to Proposed RTO with SunRegen Healthcare AG
VANCOUVER, BC / ACCESSWIRE / October 31, 2024 / Verisante Technology, Inc. (TSXV:VER.H) ("Verisante") is pleased to announce a transaction update further to it's initial news release dated August 12, 2024, that it has entered into a binding Letter of Intent ("LOI") to acquire a 100% interest in SunRegen Healthcare AG ("SunRegen"), a Swiss pharmaceutical company. The proposed transaction is a Reverse Takeover ("RTO") pursuant to Policy 5.2 of the TSX Venture Exchange and the resulting issuer intends to qualify as a Tier 2 Life Sciences Issuer.
